Table 2C.
CRP levels at baseline (0 month), and after 3 and 6 months of GnRH agonist treatment in women with PCOS, and in control subjects.
| CRP, mg/l | GnRH agonist treatment, months | |||
|---|---|---|---|---|
| 0 | 3 | 6 | ||
| PCOS | Lean | 2.0±0.3 | 1.5±0.6 | 2.3±0.3 |
| Obese | 5.9±3.0a | 11.5±4.3 | 15.0±5.0d,e | |
| Controls | Lean | 2.7±0.2b,c | 0.5±0.2 | 0.4±0.2 |
| Obese | 5.4±3.0 | 6.2±3.3 | 7.1±3.1 | |
a
Obese PCOS, 0 months vs. 6 months, P < 0.05
b
Lean Controls, 0 months vs. 3 months, P < 0.02
c
Lean Controls, 0 months vs. 6 months, P < 0.02
d
6 Months, Obese PCOS vs. Lean Controls, P < 0.02
e
6 Months, Obese PCOS vs. Lean PCOS, P < 0.03
Values are expressed as means ± SE; FFA, Free fatty acids; IL-6, Interleukin-6; CRP, C-reactive protein; GnRH agonist, gonadotropin-releasing hormone agonist; Conversion factors to SI units: CRP x9.524 (nmol/liter), IL-6 x1.311 (pmol/liter).